L-rhamnose monoclonal antibody and its preparation method and application

By obtaining and screening human natural antibody libraries, screening and heterologous expression of monoclonal antibodies, efficient L-rhamnosen monoclonal antibodies were prepared, solving the problems of detection and application complexity and dependence on human serum in the prior art. High sensitivity detection of target modification and effective inhibition of drug-resistant bacteria were achieved, demonstrating protective effects in prevention and treatment.

CN118772285BActive Publication Date: 2024-11-15SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411271510.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-11
Publication Date
2024-11-15
Estimated Expiration
2044-09-11

AI Technical Summary

Technical Problem

The methods for detecting the target L-rhamnosen modification and preparing L-rhamnosen antibodies in the prior art are complex and rely on a large amount of human serum, which limits its wide application in the field of biomedicine.

Method used

By obtaining positive human natural antibody libraries, monoclonal antibody screening, retesting and heterologous expression were performed to prepare L-rhamnosone monoclonal antibodies with high binding ability, specificity and affinity, and use pcDNA3.1 expression vector in HEK293 The antibody is expressed and purified in the cells to form an assay kit and an antibacterial drug composition.

Benefits of technology

High sensitivity detection of L-rhamnosol modification and effective inhibition of multiple drug-resistant bacteria were achieved, simplifying the production process, reducing costs, and demonstrating protective effects in preventing and treating drug-resistant bacterial infections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118772285B_ABST
    Figure CN118772285B_ABST
Patent Text Reader

Abstract

The present invention relates to an L-rhamnose monoclonal antibody and a preparation method and application thereof, and belongs to the field of biomedical technology. The L-rhamnose monoclonal antibody includes a heavy chain variable region and a light chain variable region; the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.1; the amino acid sequence of the light chain variable region is shown in SEQ ID NO.2, and the present invention also provides a method for preparing the L-rhamnose monoclonal antibody. The present invention provides an L-rhamnose monoclonal antibody with a brand-new amino acid sequence. Compared with traditional antibodies, the L-rhamnose monoclonal antibody has a stronger binding ability to the L-rhamnose antigen, can well identify the L-Rha modification of OVA and BSA proteins, and has the characteristics of high specificity, high affinity and high sensitivity. And after obtaining the coding gene sequence of the L-rhamnose monoclonal antibody, it can be directly expressed heterologously by prokaryotic cells, realizing mass preparation, short production cycle and low cost.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to an L-rhamnose monoclonal antibody and a preparation method and application thereof, belonging to the technical field of biomedicine. Background Art

[0002] Healthy adults have high levels of natural antibodies to L-rhamnose (L-rhamnose or L-Rha). Based on this property, many researchers have combined L-rhamnose (as an antibody recruiting group) with disease-related targets (such as proteins, carriers, and cells). L-rhamnose modified on the surface of the target can recruit L-rhamnose natural antibodies, thereby enhancing the destruction and immune recognition of the target through complement-dependent cytotoxicity (CDC) and / or antibody-dependent cellular phagocytosis (ADCP). Therefore, in related research and applications, whether the modification of L-rhamnose as a target is successful is the primary process.

[0003] At present, the main method for detecting target L-rhamnose modification is to purify L-rhamnose natural antibodies from human serum and perform specific detection (such as Western blot, ELISA, flow cytometry, etc.). This method requires researchers to obtain human serum and prepare L-rhamnose antibody affinity chromatography columns to purify L-rhamnose natural antibodies. The process is complicated, and there are currently no commercial L-rhamnose antibodies available. In addition, L-rhamnose antibodies also show application potential in the development of drugs for the prevention and treatment of drug-resistant bacterial infections.

[0004] Therefore, whether it is used for L-rhamnose modification detection or for antibacterial drug development, the required L-rhamnose antibodies rely on a multi-step purification process and require a large amount of human serum. This requirement seriously restricts the wide application of L-rhamnose antibodies in various fields. Therefore, a new type of L-rhamnose monoclonal antibody and a preparation method thereof are provided, which is of great significance for the detection of L-rhamnose modification and the application of L-rhamnose antibodies in antibacterial drugs. Summary of the invention

[0005] In view of the deficiencies in the prior art, the present invention provides an L-rhamnose monoclonal antibody and a preparation method and application thereof.

[0006] The technical solution of the present invention is as follows:

[0007] In a first aspect, the present invention provides an L-rhamnose monoclonal antibody, comprising a heavy chain variable region and a light chain variable region; the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.1; the amino acid sequence of the light chain variable region is shown in SEQ ID NO.2.

[0008] In a second aspect, the present invention provides a nucleic acid molecule encoding the L-rhamnose monoclonal antibody described in the first aspect.

[0009] Preferably according to the present invention, the nucleotide sequence encoding the heavy chain variable region of the above-mentioned L-rhamnose monoclonal antibody is shown as SEQ ID NO.3; the nucleotide sequence encoding the light chain variable region of the above-mentioned L-rhamnose monoclonal antibody is shown as SEQ ID NO.4.

[0010] In a third aspect, the present invention provides an expression vector, wherein the expression vector comprises the nucleic acid molecule described in the second aspect.

[0011] Preferably according to the present invention, the expression vector is pcDNA3.1.

[0012] In a fourth aspect, the present invention provides a host cell, wherein the host cell contains the expression vector described in the third aspect, or the nucleic acid molecule described in the second aspect is integrated into the genome of the host cell.

[0013] Preferably according to the present invention, the host cell is a HEK293 cell.

[0014] In a fifth aspect, the present invention provides a kit for detecting L-rhamnose modification, wherein the kit for detecting L-rhamnose modification comprises the L-rhamnose monoclonal antibody described in the first aspect.

[0015] Preferably according to the present invention, the kit for detecting L-rhamnose modification further comprises a positive control substance, a negative control substance, an antibody diluent, a color developing solution, a stop solution, a blocking solution and a washing solution.

[0016] In a sixth aspect, the present invention provides a pharmaceutical composition, comprising the L-rhamnose monoclonal antibody described in the first aspect.

[0017] Preferably according to the present invention, the pharmaceutical composition further comprises any one or a combination of at least two of a pharmaceutically acceptable carrier, excipient or diluent.

[0018] In a seventh aspect, the present invention provides a method for preparing the L-rhamnose monoclonal antibody according to the first aspect, comprising the following steps:

[0019] (1) Using L-rhamnose-BSA as an antigen to pan the human natural antibody library to obtain a positive human natural antibody library;

[0020] (2) performing monoclonal screening and retesting on the positive human natural antibody library obtained in step (1) to obtain monoclonal positive phages, and sequencing to obtain the positive monoclonal antibody nucleotide sequence;

[0021] Wherein, the positive monoclonal antibody nucleotide sequence includes the heavy chain variable region nucleotide sequence as shown in SEQ ID NO.3 and the light chain variable region nucleotide sequence as shown in SEQ ID NO.4, and the heavy chain variable region and the light chain variable region are connected by a flexible peptide, and the connection order is light chain variable region-flexible peptide-heavy chain variable region. The amino acid sequence and nucleotide sequence of the flexible peptide are shown in SEQ ID NO.5 and SEQ ID NO.6 respectively;

[0022] (3) constructing a monoclonal antibody heterologous expression vector according to the monoclonal antibody nucleotide sequence obtained in step (2), and then transforming the heterologous expression vector into a host cell, and obtaining an L-rhamnose monoclonal antibody after heterologous expression and purification.

[0023] In an eighth aspect, the present invention provides the use of the L-rhamnose monoclonal antibody described in the first aspect, the nucleic acid molecule described in the second aspect, the expression vector described in the third aspect, and the host cell described in the fourth aspect in the preparation of an L-rhamnose modified detection product or an antibacterial drug product.

[0024] The technical features and beneficial effects of the present invention are as follows:

[0025] 1. The present invention first obtains a positive human natural antibody library, and then obtains a monoclonal antibody with a new amino acid sequence against L-rhamnose through monoclonal antibody screening, retesting, sequencing and heterologous expression. The L-rhamnose monoclonal antibody has a strong binding ability to the L-rhamnose antigen, can well identify the L-Rha modification of chicken ovalbumin (OVA) and bovine serum albumin (BSA), and has the characteristics of high specificity, high affinity and high sensitivity. After obtaining the coding gene sequence of the L-rhamnose monoclonal antibody, it can be directly prepared in large quantities through heterologous expression, with a short production cycle and low cost.

[0026] 2. The L-rhamnose monoclonal antibody provided by the present invention can recognize and bind to the L-rhamnose structure on the surface of drug-resistant bacteria, and thus has a strong inhibitory killing ability against a variety of drug-resistant bacteria including Pseudomonas aeruginosa, Escherichia coli and Streptococcus pneumoniae, and has the advantages of broad spectrum and good killing effect. In addition, the mouse experiment confirmed that intravenous injection of L-rhamnose monoclonal antibody into mice can effectively resist the infection of Pseudomonas aeruginosa, has a certain protective effect on mice, and can be used to prepare drugs for preventing and / or treating drug-resistant bacterial infections. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 This is an electrophoresis diagram of the PCR amplification products of the heavy chain variable region and the light chain variable region of the L-rhamnose monoclonal antibody of the present invention;

[0028] In the figure, A is a gel electrophoresis diagram of the PCR amplification product of the heavy chain variable region, and B is a gel electrophoresis diagram of the PCR amplification product of the light chain variable region.

[0029] Figure 2 Schematic diagram of the L-rhamnose monoclonal antibody expression vector of the present invention;

[0030] In the figure, A is a schematic diagram of the structure of the plasmid vector pcDNA3.1-Rha-H002-hIgG1-VH; B is a schematic diagram of the structure of the plasmid vector pcDNA3.1-Rha-H002-hKappa-VL.

[0031] Figure 3 This is a diagram showing the results of SDS-PAGE detection of the purified L-rhamnose monoclonal antibody of the present invention.

[0032] Figure 4 This is a diagram showing the results of detecting L-rhamnose modification by the L-rhamnose monoclonal antibody of the present invention;

[0033] In the figure, A is the ELISA test result, and B is the Western blot test result.

[0034] Figure 5 This is a graph showing the results of the L-rhamnose monoclonal antibody of the present invention resisting Pseudomonas aeruginosa attack. DETAILED DESCRIPTION

[0035] The specific implementation modes of the present invention are described below so that those skilled in the art can understand the present invention. However, it should be clear that the present invention is not limited to the scope of the specific implementation modes. For those of ordinary skill in the art, as long as various changes are within the spirit and scope of the present invention as defined and determined by the attached claims, these changes are obvious, and all inventions and creations utilizing the concept of the present invention are protected.

[0036] Unless otherwise specified, the raw materials and reagents used in the examples are conventional raw materials and reagents and can be purchased commercially; the methods described are all prior art unless otherwise specified.

[0037] Escherichia coli XL1-Blue is available from Shanghai Bio-Tech Biotechnology Co., Ltd.

[0038] VCSM13 helper phage is available from Changsha Abiwei Biotechnology Co., Ltd.

[0039] Human natural antibody library, available from Albertsons Biotechnology Co., Ltd.

[0040] Example 1. Screening of monoclonal antibodies

[0041] 1. Preparation of L-rhamnose-BSA and L-rhamnose-OVA

[0042] L-Rha (1) is protected by acetyl group (2) and glycosylated by SnCl2-catalyzed PhSH to obtain thiorhamnoside (product 3); product 3 is connected with azide molecule 4 to obtain intermediate product 5 (L-Rha-N3); intermediate product 5 is deprotected and reduced to obtain product 6 (L-Rha-NH2) with an amine terminal; product 6 reacts with succinic anhydride to obtain product 7 with a carboxylic acid terminal; product 7 is activated by TSTU to obtain N-hydroxysuccinimide (NHS)-activated L-Rha donor 8 (L-Rha-NHS). The specific preparation process is shown in the following formula:

[0043] .

[0044] 10 mg of L-Rha donor 8 was dissolved in 1 mL of 3×PBS buffer (pH 7.4) to obtain a 10 mg / mL L-Rha donor 8 solution; 10 mg of chicken ovalbumin (OVA) or bovine serum albumin (BSA) was dissolved in 1 mL of 3×PBS buffer (pH 7.4) to obtain a 10 mg / mL OVA solution or BSA solution; the L-Rha donor 8 solution was mixed with the OVA solution or BSA solution to construct a reaction system, and then the reaction system was slowly stirred at room temperature for 1 hour, and then transferred to a 3 kDa ultrafiltration tube and filtered at 3500 °C. g , centrifuged at 4°C for 30 min; then the buffer was replaced with 1× PBS (pH 7.4) and incubated at 3500 g , centrifuge at 4°C for 30 min, repeat three times to obtain L-rhamnose-BSA (L-Rha-BSA) or L-rhamnose-OVA (L-Rha-OVA).

[0045] 2. Introduction, amplification and quality analysis of human natural antibody library

[0046] The human natural antibody library uses phage display technology to collect peripheral blood mononuclear cells from healthy adults and separate B lymphocytes from them. The antibody heavy chain variable region (VH) and light chain variable region (VL) of B lymphocytes are amplified by PCR, and the amplified fragments are inserted into the phage vector. The antibody molecule Fab fragment or single-chain antibody (scFv) and the single-chain phage coat protein are displayed on the phage surface in the form of a fusion protein. The specific method is as follows:

[0047] A 1% suspension of the human natural antibody library was added to the Escherichia coli XL1-Blue in the logarithmic growth phase, and the suspension was allowed to stand at 37°C for 30 minutes, and then cultured with shaking at 37°C and 250 rpm for 2 hours; then, VCSM13 helper phage was added, and the suspension was allowed to stand at 37°C for 30 minutes, and then cultured with shaking at 37°C and 250 rpm for 1.5 hours; after centrifugation, the supernatant was discarded, and 2YT-ATK medium was added to the precipitate, and cultured overnight at 30°C and 225 rpm; after overnight culture, the bacterial solution was centrifuged, and the supernatant was the amplified human natural antibody library.

[0048] Take 10 μL of human natural antibody library and dilute it 10 times (10 μL + 990 μL) using 2×YT medium. 8 After 10 times, 10 μL of the dilution was taken to infect 100 μL of E. coli XL1-Blue. After 30 minutes of infection, the mixture was spread on 2×YT-ATG semi-solid medium. The number of monoclonal colonies was counted the next day to calculate the phage concentration of the human natural antibody library.

[0049] In this embodiment, the quality analysis result of the amplified library is: amplified library phage concentration = monoclonal colony count × unit volume dilution factor = 324 × (10 8 × 100) = 3.24 × 10 12 CFU / mL.

[0050] 3. Obtaining positive human natural antibody library

[0051] The high-affinity ELISA plate was coated with antigen L-rhamnose-BSA overnight, then washed with 0.1% PBST buffer and blocked with 3% skim milk powder at room temperature for 1 hour. The blocking solution was discarded and the plate was washed for later use. Approximately 5×10 12 CFU human natural antibody amplification library, incubate at 37℃ for 2 hours; wash the plate with 0.1% PBST buffer, elute the bound phage with Glycine-HCl buffer, and adjust the pH to 7.4 with Tris-HCl buffer; mix the obtained eluate with Escherichia coli XL1-Blue, incubate at 37℃ for 30 minutes; shake and culture overnight at 30℃ to obtain the first-generation library of panning; cycle the above steps twice to obtain the second-generation library and the third-generation library of panning in turn; then perform ELISA test on the third-generation library to screen positive human natural antibodies that meet the specificity requirements and obtain a positive human natural antibody library. The ELISA detection method is an existing method, and the ELISA detection results are shown in Table 1.

[0052] Table 1

[0053]

[0054] 4. Monoclonal antibody screening, retesting and sequencing

[0055] The positive human natural antibody library obtained in step 3 is used as a sample for phage expression, and the supernatant after phage expression is used for ELISA detection, and positive monoclonal antibodies are further selected from the positive human natural antibody library. The specific steps are as follows:

[0056] Coating antigen L-Rha-OVA: The concentration of L-Rha-OVA coated on a 96-well ELISA plate was 0.5 μg / mL at 4°C overnight;

[0057] Blocking: Add 340 μL of 3% skim milk powder to each well for 1 hour at room temperature;

[0058] Sample addition: dilute the supernatant after phage expression 10 times, add 100 μL of the diluted supernatant to each well, and incubate at room temperature for 1 hour;

[0059] Add secondary antibody: add 100 μL M13 phage antibody (M13-HRP, 0.2 μg / mL) to each well and incubate at room temperature for 1 hour;

[0060] TMB colorimetric solution: Add 200 μL of colorimetric solution to each well. After 20 minutes of color development, add 50 μL of color stop solution. Use dual wavelengths of 450 nm and 630 nm to detect absorbance.

[0061] The phage expression method is the same as step 3, and the ELISA detection method in the monoclonal screening process is the existing method. The ELISA detection results are shown in Table 2.

[0062] Table 2

[0063]

[0064] In this example, an L-rhamnose monoclonal antibody with high titer binding to L-Rha-OVA was screened and recorded as A2. Then, the L-rhamnose monoclonal antibody A2 was competitively retested, and it was found that L-Rha could compete with L-Rha-OVA for binding to A2; finally, A2 was sequenced to obtain the scFv sequence of the L-rhamnose monoclonal antibody A2. Among them, the competitive retest method is an existing method, and the results of the competitive retest are shown in Table 3.

[0065] Table 3

[0066]

[0067] After sequencing, the amino acid sequence of the heavy chain variable region of the L-rhamnose monoclonal antibody A2 in this example is shown as SEQ ID NO.1, and the nucleotide sequence encoding the heavy chain variable region is shown as SEQ ID NO.3; the amino acid sequence of the light chain variable region is shown as SEQ ID NO.2, and the nucleotide sequence encoding the light chain variable region is shown as SEQ ID NO.4.

[0068] Example 2: Heterologous expression of L-rhamnose monoclonal antibody A2

[0069] 1. Expression vector construction

[0070] The heavy chain variable region and light chain variable region of the L-rhamnose monoclonal antibody A2 were introduced into the expression vector pcDNA3.1 to obtain a recombinant expression vector containing the L-rhamnose monoclonal antibody A2. The specific method is as follows:

[0071] The nucleotide sequences of the heavy chain variable region and the light chain variable region of the L-rhamnose monoclonal antibody A2 as shown in SEQ ID NO.3 and SEQ ID NO.4 were artificially synthesized by Nanjing Qingke Biotechnology Co., Ltd., and then PCR amplification was performed using the nucleotide sequences of the heavy chain variable region and the light chain variable region of the L-rhamnose monoclonal antibody A2 as templates to obtain the Rha-002-VH sequence and the Rha-002-VL sequence; the Rha-002-VH sequence and the Rha-002-VL sequence were verified by electrophoresis, and the results were as follows: Figure 1 shown.

[0072] Among them, the light chain variable region amplification primers are:

[0073] F:5'-GCTAGCGTTTAAACTTAAGCTTGCCACCATGGGCTGGTCCCTGATTCTGCTGTTCCTGG-3' (SEQ ID NO.9);

[0074] R: 5'-AACGGGCCCTCTAGACTCGAGTCAACACTCGCCTCTGTT-3' (SEQ ID NO. 10);

[0075] The heavy chain variable region amplification primers are:

[0076] F: 5'-GCTAGCGTTTAAACTTAAGCTTGCCACCATGGGCTGGTCCCTGATTCTGCTGTTCCTGG-3' (SEQ ID NO. 11).

[0077] R: 5'-AAACGGGCCCTCTAGACTCGAGTTACTTTCCCGGAGACAGGGA-3' (SEQ ID NO. 12).

[0078] The amplification system and amplification program are shown in Tables 4 and 5.

[0079] Table 4

[0080]

[0081] Table 5

[0082]

[0083] Depend on Figure 1 It can be seen that the Rha-002-VH sequence and the Rha-002-VL sequence were amplified successfully.

[0084] Then, the Rha-002-VH sequence was overlapped with the hIgG1 sequence to obtain the Rha-H002-hIgG1-VH sequence; the Rha-002-VL sequence was overlapped with the hKappa sequence to obtain the Rha-H002-hKappa-VL sequence; the pcDNA3.1 vector, the Rha-H002-hIgG1-VH sequence and the Rha-H002-hKappa-VL sequence were double-digested with HindIII / XhoI, the double-digestion system was mixed and reacted at 37°C for 15 minutes, and then gel-cutting was performed; the vector recovered from gel-cutting was connected with the connection fragment by recombinase, and reacted at 50°C for 20 minutes to obtain the recombinant expression vectors pcDNA3.1-Rha-H002-hIgG1-VH and pcDNA3.1-Rha-H002-hKappa-VL. The structures of the two vectors are shown in FIG. Figure 2 shown.

[0085] The double enzyme digestion system is shown in Table 6, and the recombinase ligation system is shown in Table 7. The hIgG1 sequence and hKappa sequence are shown in SEQ ID NO. 7 and SEQ ID NO. 8, respectively.

[0086] Table 6

[0087]

[0088] Table 7

[0089]

[0090] Finally, the recombinant expression vector containing L-rhamnose monoclonal antibody A2 was transformed into DH5α competent cells, the transformed plates were picked with bacteria, and the cloned bacterial solution was sent to a sequencing company for sequencing verification.

[0091] 2. Heterologous expression preparation

[0092] The recombinant expression vectors pcDNA3.1-Rha-H002-hIgG1-VH and pcDNA3.1-Rha-H002-hKappa-VL were mixed with the transfection reagent and added to HEK293 cells. On the 1st, 3rd and 5th days after transfection, 293 serum-free CD medium was added for shake flask culture. The shake flask culture conditions were: 5% CO2, temperature 37°C, and shaker speed 175 rpm. The cultured HEK293 cell supernatant was centrifuged and filtered with a 0.22 μm filter membrane. The filtered supernatant was purified by Protein G column, specifically: washing with 5 column volumes of deionized water to remove air and 20% ethanol, balancing the column with 10 column volumes of PBS buffer (pH=7.4), and flowing through the Protein G column at a rate of 0.5 mL / min. G column, equilibrate the column with PBS buffer again, elute the bound protein with 0.1M glycine; collect the eluted sample, dialyze overnight at 4°C, the dialysis buffer is PBS; the dialyzed sample is concentrated by ultrafiltration (ultrafiltration tube), and the purity of the target protein is detected by SDS-PAGE gel. The results are as follows: Figure 3 shown.

[0093] Depend on Figure 3 It can be seen that the present invention successfully prepared L-rhamnose monoclonal antibody A2 through a heterologous expression method.

[0094] Example 3: Detection of L-rhamnose modification using L-rhamnose monoclonal antibody A2

[0095] 1. ELISA method: Add L-Rha-BSA or L-Rha-OVA to the ELISA plate at 100 μL / well and coat at 4°C overnight; wash twice with PBST buffer, pat dry, add 3% skim milk powder at 340 μL / well, and incubate at room temperature for 1 hour; wash twice with PBST buffer, pat dry, add L-rhamnose monoclonal antibody A2 diluted to 1 μg / mL at 100 μL / well, and incubate at room temperature for 1 hour; wash twice with PBST buffer, pat dry, add human IgG-Fc-HRP diluted to 1 μg / ml at 100 μL / well, and incubate at room temperature for 1 hour; wash three times with PBST clear buffer, pat dry, add TMB colorimetric solution at 100 μL / well, and react at room temperature for 20 minutes; add 2 M sulfuric acid at 50 μL / well; read on the ELISA reader within 15 minutes at a wavelength of 450 nm. The results are as follows: Figure 4 As shown in A.

[0096] Depend on Figure 4As shown in A, L-rhamnose monoclonal antibody A2 has a significant binding titer to L-Rha-BSA and L-Rha-OVA.

[0097] 2. Western blot method: The protein samples L-Rha-BSA, L-Rha-OVA, BSA, and OVA were mixed with loading buffer, boiled for 5 minutes, and loaded onto SDS-PAGE gel for electrophoresis separation; the proteins separated by electrophoresis were transferred to PVDF membrane, and the transfer conditions were 4°C, 100V, and 90 minutes; 5% skim milk powder was dissolved in TBST buffer, the amount was 340 μL / well, and the membrane was blocked at room temperature for 1 hour; the membrane was incubated in L-rhamnose monoclonal antibody A2 solution diluted to 1 μg / ml overnight, and shaken slowly at 4°C; the membrane was washed with TBST buffer 3 times, 10 minutes each time; the membrane was incubated in human IgG-Fc-HRP diluted to 1 μg / ml for 1 hour, and shaken slowly at room temperature; the membrane was washed with TBST buffer 3 times, 10 minutes each time; the ECL colorimetric solution was evenly covered on the membrane and allowed to stand for 1 minute; the imaging system was used for detection and image acquisition, and the results were as follows: Figure 4 As shown in B.

[0098] Depend on Figure 4 As shown in B, L-rhamnose monoclonal antibody A2 specifically binds to L-Rha-BSA and L-Rha-OVA, but does not bind to BSA and OVA.

[0099] Example 4: Verification of the antibacterial function of L-rhamnose monoclonal antibody A2

[0100] Experimental animals: 8-week-old female Balb / c mice were used.

[0101] Experimental groups: L-rhamnose monoclonal antibody group (McAb), 8 mice; PBS buffer group (PBS), 8 mice.

[0102] Experimental procedures: The mice in the McAb group were injected with 100 μg of L-rhamnose monoclonal antibody A2 (concentration 1 mg / mL) through the tail vein, and the mice in the PBS group were injected with an equal volume of PBS buffer; then, the lungs were challenged with Pseudomonas aeruginosa PAO1 by tracheal intubation instillation, with a challenge dose of 1.25×10 7 CFU; observe for 7 days, record the survival of mice and draw a survival curve. Figure 5 shown.

[0103] Depend on Figure 5It can be seen that compared with the PBS group, the survival rate of mice in the McAb group was significantly improved, indicating that the L-rhamnose monoclonal antibody A2 of the present invention can effectively resist the infection of Pseudomonas aeruginosa, has a certain protective effect on mice, and can be used to prepare drugs for preventing and / or treating drug-resistant bacterial infections.

Claims

1. A L-rhamnose monoclonal antibody, characterized in that: The L-rhamnose monoclonal antibody comprises a heavy chain variable region and a light chain variable region; the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.1; the amino acid sequence of the light chain variable region is shown in SEQ ID NO.

2.

2. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the L-rhamnose monoclonal antibody according to claim 1.

3. The nucleic acid molecule according to claim 2, characterized in that The nucleotide sequence encoding the heavy chain variable region of the L-rhamnose monoclonal antibody according to claim 1 is shown in SEQ ID NO.3; The nucleotide sequence encoding the light chain variable region of the L-rhamnose monoclonal antibody according to claim 1 is shown in SEQ ID NO.

4.

4. An expression vector, characterized in that: The expression vector comprises the nucleic acid molecule of claim 2.

5. A host cell, characterized in that The host cell contains the expression vector according to claim 4, or the nucleic acid molecule according to claim 3 is integrated into the genome of the host cell.

6. A kit for detecting L-rhamnose modification, characterized in that: The kit for detecting L-rhamnose modification comprises the L-rhamnose monoclonal antibody according to claim 1.

7. The kit for detecting L-rhamnose modification according to claim 6, characterized in that: The kit for detecting L-rhamnose modification also includes a positive control substance, a negative control substance, an antibody diluent, a color developing solution, a stop solution, a blocking solution and a washing solution.

8. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the L-rhamnose monoclonal antibody according to claim 1.

9. Use of the L-rhamnose monoclonal antibody according to claim 1, the nucleic acid molecule according to claim 2, the expression vector according to claim 4 or the host cell according to claim 5 in preparing an L-rhamnose modified detection product or an antibacterial drug product.